A 65-year-old man presents to the emergency department with severe dizziness and dyspnea. He is diaphoretic and lethargic. His assessment findings are shown below. Which medication is the priority to administer to stabilize this patient's vital signs?

Question Analysis and Rationale for the Correct Answer

The patient is hypotensive at 80/50 mmHg with marked bradycardia at 35 beats/min, and is in shock with lethargy and diaphoresis. The ECG confirms sinus bradycardia, while the serum potassium is normal at 4.0 mEq/L and Troponin-I is also normal, making myocardial infarction or hyperkalemia-induced bradycardia unlikely. The core problem is therefore hemodynamically unstable, symptomatic bradycardia, and correcting it rapidly is the top priority.

Drug Mechanism and Basis for Selection

Atropine is an anticholinergic agent that blocks muscarinic acetylcholine receptors, antagonizing vagal inhibition of the heart to increase the spontaneous firing rate of the SA node and enhance AV conduction. The resulting rise in heart rate improves cardiac output and blood pressure, making it the first-line drug for symptomatic sinus bradycardia. The supporting literature^[2] reports a case of grayanotoxin poisoning in which the patient developed hypotension and bradycardia with a blood pressure of 60/40 mmHg and a heart rate of 42 beats/min, illustrating how sustained vagal activation can produce hemodynamic instability. In bradycardia driven by excessive vagal tone, atropine serves as a highly effective antagonist.

Analysis of Incorrect Options

- Digoxin: Inhibits Na⁺/K⁺-ATPase to increase myocardial contractility, but it also enhances vagal tone and slows AV conduction, risking worsening of the bradycardia.
- Adenosine: Transiently blocks AV nodal conduction to terminate supraventricular tachycardia; giving it to a bradycardic patient is contraindicated because it may precipitate asystole.
- Lidocaine: A sodium channel blocker used for ventricular arrhythmias, with no indication in the treatment of sinus bradycardia.
- Amiodarone: A broad-spectrum antiarrhythmic that primarily blocks potassium channels and also has beta-blocking effects, which can further slow the heart rate, so it is not used in bradycardic patients.

Clinical Application and Pathophysiology in Depth

Symptomatic bradycardia reduces cardiac output, leading to decreased cerebral perfusion (lethargy, dizziness), reduced coronary perfusion, and systemic hypoperfusion (diaphoresis, hypotension). The grayanotoxin poisoning cases described in sources^[1] and ^[2] serve as an excellent model for understanding this pathophysiology. This toxin holds neuronal sodium channels in the open state, excessively activating the vagus nerve, which lowers the SA node firing rate and delays AV conduction, producing severe bradycardia and hypotension. Although grayanotoxin toxicity is not the direct cause in this patient, the end result is a comparable state of hemodynamic collapse from vagal overactivity, so rapid antagonism with the anticholinergic atropine is the life-saving treatment principle. In addition, BRASH syndrome, discussed in source^[3], is a vicious cycle of bradycardia, shock, and hyperkalemia that must always be considered in the differential when both blood pressure and heart rate are low, as in this patient; however, because this patient's potassium is normal, treatment should focus on pure symptomatic bradycardia rather than BRASH syndrome. The case of profound drug interaction–induced bradycardia described in source^[4] likewise demonstrates that hemodynamic collapse can occur when multiple agents suppress the cardiac conduction system, indicating the need to discontinue the offending drugs along with immediate pharmacologic intervention such as atropine.